

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Depemokimab for treating chronic rhinosinusitis with nasal polyps ID6449

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
GlaxoSmithKline (depemokimab) Patient/carer groups	All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation
Allergy UK	Board of Community Health Councils in
Asthma + Lung UK	Wales
Asthma Relief Charity	British National Formulary
NARA – The Breathing Charity	Care Quality Commission
Samter's Society	Department of Health - Northern Ireland
Sinus UK	Healthcare Improvement Scotland
SmellTaste	Medicines and Healthcare products
South Asian Health Foundation	Regulatory Agency
Specialised Healthcare Alliance	National Association of Primary Care
'	National Pharmacy Association
Healthcare professional groups	NHS Confederation
Association of Anaesthetists	NHS Wales Joint Commissioning
Association of Respiratory Nurse	Committee
Specialists	Scottish Medicines Consortium
 Association of Surgeons of Great Britain and Ireland 	Welsh Government
Association for Respiratory	Possible comparator companies
Technology and Physiology	Sanofi (Dupilumab
British Association of	
Otolaryngologists, Head & Neck	Relevant research groups
Surgeons	Asthma, Allergy and Inflammation
British Geriatrics Society	Research Trust
British Society for Allergy and Clinical	Cochrane Airways Group
Immunology	Genomics England
• ENT UK	MRC Clinical Trials Unit
Primary Care Respiratory Society UK	National Institute for Health Research
Royal College of Anaesthetists	Associated Dublic Hashbarras
Royal College of General Practitioners	Associated Public Health groups
Royal College of Nursing	Public Health Wales No and the Constitution of the Consti
Royal College of Pathologists	UK Health Security Agency
Royal College of Physicians	
Royal College of Surgeons	

Provisional stakeholder list for the evaluation of depemokimab for treating chronic rhinosinusitis with nasal polyps ID6449



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association 	
Others Department of Health and Social Care NHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).


All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

<u>Commentators</u>

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example,

Provisional stakeholder list for the evaluation of depemokimab for treating chronic rhinosinusitis with nasal polyps ID6449





the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.